Printer Friendly

Intraop Medical Introduces the Mobetron System at the Canadian Association of Radiation Oncologists.

SUNNYVALE, Calif. -- Intraop Medical Corporation (IOPM.OB) have introduced the Mobetron(R), an innovative machine used to deliver intraoperative radiation treatment (IORT), to Canadian radiation oncologists and medical physicists at the recent annual scientific meeting of the Canadian Association of Radiation Oncologists (CARO), in Victoria, B.C., September 7-10, 2005.

The Mobetron delivers electron beam radiation during surgery for cancer. This procedure is called intraoperative radiation therapy or IORT. In IORT, because the normal tissues surrounding the tumor can be displaced or protected, a single two-minute IORT treatment can often eliminate several weeks of conventional pre- or post-operative external beam radiation therapy (EBRT). IORT has been used in Europe and the USA for many years to treat advanced cancer. Now, a new use of IORT to treat early stage breast cancer is being investigated and was shown to the CARO attendees.

During a lumpectomy for early stage breast cancer, an electron beam, a form of radiation, is applied to the small surgical area as soon as the tumor lump has been removed. A large dose of radiation delivered over approximately two minutes can be directly applied to the small cavity where the breast lump was removed in order to kill any microscopic disease that may remain in the surgical excision area. The radiation is concentrated to a small area to avoid harming overlying tissue such as skin or underlying organs such as the lungs.

The treatment takes place in the operating room while the patient is still under anesthesia and only adds about 20 minutes to the entire surgical procedure. It may also decrease the number of external beam radiation treatments that patients will have to undergo to prevent local recurrence of the cancer. In comparison, traditional intraoperative radiation is performed in a separate room from the operating room adding one to two hours to the operation time. The hospital must also have multiple shielding and protection in a traditional radiation room, where as the Mobetron can be used in the main operating room because it requires no shielding from the radiation.

Chapple Musslewhite, U.S. Sales Manager for Intraop Medical, commented "This was an excellent opportunity to introduce the Mobetron System to a new market. We found that the radiation oncologists and medical physicists in Canada with whom we spoke are very interested in learning more about this technology and IORT treatment ".

About Intraop Medical Corporation

Intraop Medical Corporation is improving the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron beam system designed for intraoperative radiation therapy (IORT) treatment of cancer, coronary/vascular restenosis and other medical applications. IORT is the direct application of radiation to a tumor while a patient is undergoing cancer surgery. Intraop Medical Corporation has revolutionized this procedure by developing the first mobile device for delivering IORT in the operating room without the necessity of adding extensive radiation shielding. The Mobetron is easily transportable between operating rooms and/or hospitals, further increasing system usage. The system is FDA approved for sale in the United States and has received the equivalent foreign approvals; CE Mark in Europe, JIS in Japan and SDA in China. Intraop Medical Corporation is based in Santa Clara, California. For more information on Intraop Medical Corporation please visit: www.intraopmedical.com.

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the company to execute its plans. By making these forward-looking statements, the company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 22, 2005
Words:654
Previous Article:Zacks Buy List Highlights: GATX Corp., Too, Inc., Marvell Technology Group Ltd., and Waters Corp.
Next Article:Zacks Sell List Highlights Owens-Illinois, Pactiv, CEC Entertainment, and Premiere Global Services.


Related Articles
Protein predicts prostate cancer spread.
RELIEF FOR CANCER PATIENTS NEW BUILDING TO EXPAND, CENTRALIZE CARE SERVICES.
"Heart rhythm" & "J. of the American College of Radiology".
TUMOR ZAPPER.
The history of radiation oncology.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters